- WuXi Biologics announced that an innovative trispecific antibody for ophthalmic diseases developed with Earendil Labs became the 1,000th molecule on its integrated CRDMO platform.
- The collaboration has advanced multiple bispecific and multispecific antibodies, fusion proteins, and antibody-drug conjugates (ADCs) from DNA to IND across ophthalmology, autoimmune diseases, oncology, and other serious conditions.
WuXi Biologics announced that an innovative trispecific antibody for ophthalmic diseases developed in collaboration with Earendil Labs has become the 1,000th molecule on its integrated CRDMO platform. The companies said their collaboration has advanced multiple novel bispecific and multispecific antibodies, fusion proteins, and antibody-drug conjugates (ADCs) from DNA to investigational new drug (IND) stage, with timelines that outperformed industry averages.
According to the companies, the partnership combines Earendil Labs’ discovery capabilities with WuXi Biologics’ integrated research, development, and contract manufacturing platform to support the progression of programs across autoimmune diseases, oncology, ophthalmic diseases, and other serious conditions. The companies said the collaboration aims to reduce development risk and accelerate development timelines.
“Reaching the 1,000th molecule milestone is a significant moment in our journey of enabling global innovation. It reflects the confidence that our global partners place in WuXi Biologics’ integrated CRDMO platform, a robust quality system and consistent execution.”
Dr. Chris Chen, CEO of WuXi Biologics
The companies said they plan to continue expanding their collaboration to support the development of next-generation biologics. Earendil Labs stated that the partnership provides a foundation for advancing AI-enabled protein therapeutics discovery into therapeutic candidates and accelerating additional programs toward clinical development.
